[{"id":"24c0fcb4-b357-4530-a6a0-668b57518e71","acronym":"ARC-27","url":"https://clinicaltrials.gov/study/NCT06120075","created_at":"2023-11-07T16:14:23.781Z","updated_at":"2025-02-25T17:32:32.864Z","phase":"Phase 1","brief_title":"A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies","source_id_and_acronym":"NCT06120075 - ARC-27","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" EGFR • PD-L1 • ALK • MET • RET • ROS1 • STK11 • NTRK","pipe":" | ","alterations":" EGFR mutation • STK11 mutation • ALK mutation","tags":["EGFR • PD-L1 • ALK • MET • RET • ROS1 • STK11 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • STK11 mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Yutuo (zimberelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 91","initiation":"Initiation: 01/19/2024","start_date":" 01/19/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-01-30"},{"id":"4b3b972a-c804-49a8-a2d6-60b8eae4c32b","acronym":"KEYNOTE-C62","url":"https://clinicaltrials.gov/study/NCT05860296","created_at":"2023-05-16T17:06:31.720Z","updated_at":"2025-02-25T16:18:48.260Z","phase":"Phase 1/2","brief_title":"Testing Experimental Anti-cancer Drug SLC-391 with an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers","source_id_and_acronym":"NCT05860296 - KEYNOTE-C62","lead_sponsor":"SignalChem Lifesciences Corporation","biomarkers":" PD-L1 • KRAS • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1 • KRAS • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SLC-391"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 05/31/2023","start_date":" 05/31/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2024-11-19"},{"id":"6ae91b16-28e3-42da-b2eb-0dd1d16d9e97","acronym":"","url":"https://clinicaltrials.gov/study/NCT05826015","created_at":"2023-04-24T14:03:55.315Z","updated_at":"2024-07-02T16:34:26.698Z","phase":"Phase 1","brief_title":"AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer","source_id_and_acronym":"NCT05826015","lead_sponsor":"Washington University School of Medicine","biomarkers":" HER-2 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["HER-2 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • batiraxcept (AVB-500)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 10/31/2024","start_date":" 10/31/2024","primary_txt":" Primary completion: 06/03/2029","primary_completion_date":" 06/03/2029","study_txt":" Completion: 06/04/2034","study_completion_date":" 06/04/2034","last_update_posted":"2024-06-12"},{"id":"e726abe0-9a61-4e1d-8970-9b7613e8839f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03522142","created_at":"2021-01-18T17:20:30.581Z","updated_at":"2024-07-02T16:34:37.560Z","phase":"Phase 1","brief_title":"A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies","source_id_and_acronym":"NCT03522142","lead_sponsor":"Incyte Corporation","biomarkers":" FLT3 • MSI • IDH1 • IDH2","pipe":" | ","alterations":" MSI-H/dMMR • FLT3-ITD mutation • FLT3 wild-type • IDH wild-type","tags":["FLT3 • MSI • IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • FLT3-ITD mutation • FLT3 wild-type • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • INCB81776"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 08/27/2018","start_date":" 08/27/2018","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-06"},{"id":"8abb3331-04ba-4bfa-a734-5fadb9a6b09e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04458259","created_at":"2021-08-31T17:53:09.115Z","updated_at":"2024-07-02T16:35:11.509Z","phase":"Phase 1","brief_title":"Study of PF-07265807 in Participants With Metastatic Solid Tumors.","source_id_and_acronym":"NCT04458259","lead_sponsor":"Pfizer","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib • Zumrad (sasanlimab) • PF-07265807"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 09/24/2020","start_date":" 09/24/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-03"},{"id":"9730baae-2de2-46a9-bf0b-7ec41e574909","acronym":"","url":"https://clinicaltrials.gov/study/NCT02922777","created_at":"2021-01-18T14:21:04.826Z","updated_at":"2024-07-02T16:35:18.338Z","phase":"Phase 1","brief_title":"Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.","source_id_and_acronym":"NCT02922777","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • bemcentinib (BGB324)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 02/06/2023","primary_completion_date":" 02/06/2023","study_txt":" Completion: 04/04/2023","study_completion_date":" 04/04/2023","last_update_posted":"2024-02-21"},{"id":"b467a2c6-7621-4f9d-a068-1886d5c9de0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02729298","created_at":"2021-01-18T13:21:39.360Z","updated_at":"2024-07-02T16:35:29.379Z","phase":"Phase 1","brief_title":"First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT02729298","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dubermatinib (TP-0903)"],"overall_status":"Completed","enrollment":" Enrollment 177","initiation":"Initiation: 12/14/2016","start_date":" 12/14/2016","primary_txt":" Primary completion: 06/29/2022","primary_completion_date":" 06/29/2022","study_txt":" Completion: 06/29/2022","study_completion_date":" 06/29/2022","last_update_posted":"2023-11-14"},{"id":"a244e177-3024-4585-8143-53da436ade5d","acronym":"MK-3475 PN531","url":"https://clinicaltrials.gov/study/NCT03184571","created_at":"2021-01-17T17:21:07.066Z","updated_at":"2025-02-25T16:06:25.427Z","phase":"Phase 2","brief_title":"Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC","source_id_and_acronym":"NCT03184571 - MK-3475 PN531","lead_sponsor":"BerGenBio ASA","biomarkers":" EGFR • PD-L1 • ALK • AXL","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • bemcentinib (BGB324)"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 10/17/2017","start_date":" 10/17/2017","primary_txt":" Primary completion: 10/27/2022","primary_completion_date":" 10/27/2022","study_txt":" Completion: 10/27/2022","study_completion_date":" 10/27/2022","last_update_posted":"2023-10-09"},{"id":"a2c0ab58-6cde-42b8-9e69-6e1ed22c988f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05469178","created_at":"2022-07-21T11:55:16.592Z","updated_at":"2024-07-02T16:35:34.196Z","phase":"Phase 1b/2a","brief_title":"A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05469178","lead_sponsor":"BerGenBio ASA","biomarkers":" PD-L1 • STK11","pipe":" | ","alterations":" STK11 mutation","tags":["PD-L1 • STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • pemetrexed • bemcentinib (BGB324)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 12/14/2022","start_date":" 12/14/2022","primary_txt":" Primary completion: 08/11/2025","primary_completion_date":" 08/11/2025","study_txt":" Completion: 08/11/2025","study_completion_date":" 08/11/2025","last_update_posted":"2023-10-09"},{"id":"4d0513e0-80e4-4c43-823b-9318af895a28","acronym":"AVB500-OC-002","url":"https://clinicaltrials.gov/study/NCT03639246","created_at":"2021-01-18T17:52:08.158Z","updated_at":"2024-07-02T16:35:55.705Z","phase":"Phase 1b/2","brief_title":"Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer","source_id_and_acronym":"NCT03639246 - AVB500-OC-002","lead_sponsor":"Aravive, Inc.","biomarkers":" GAS6","pipe":"","alterations":" ","tags":["GAS6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • pegylated liposomal doxorubicin • batiraxcept (AVB-500) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 12/06/2018","start_date":" 12/06/2018","primary_txt":" Primary completion: 01/08/2021","primary_completion_date":" 01/08/2021","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2023-02-13"},{"id":"e65ca9a7-1045-4f86-8887-7faabd39cc38","acronym":"","url":"https://clinicaltrials.gov/study/NCT04518345","created_at":"2021-01-18T21:38:55.797Z","updated_at":"2024-07-02T16:35:56.436Z","phase":"Phase 1b/2","brief_title":"TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT04518345","lead_sponsor":"Uma Borate","biomarkers":" FLT3 • CD4","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • dubermatinib (TP-0903)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 11/05/2020","start_date":" 11/05/2020","primary_txt":" Primary completion: 10/13/2021","primary_completion_date":" 10/13/2021","study_txt":" Completion: 12/22/2021","study_completion_date":" 12/22/2021","last_update_posted":"2023-02-06"},{"id":"cb891da4-f394-4111-b6a4-11ba3bb24834","acronym":"BGBC004","url":"https://clinicaltrials.gov/study/NCT02424617","created_at":"2021-01-18T11:35:53.199Z","updated_at":"2025-02-25T16:24:32.626Z","phase":"Phase 1/2","brief_title":"A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02424617 - BGBC004","lead_sponsor":"BerGenBio ASA","biomarkers":" EGFR • GAS6","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M","tags":["EGFR • GAS6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • erlotinib • bemcentinib (BGB324)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 08/25/2021","primary_completion_date":" 08/25/2021","study_txt":" Completion: 08/25/2021","study_completion_date":" 08/25/2021","last_update_posted":"2022-08-18"},{"id":"c36bb106-df7a-452b-8b1f-240d487bcc1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02929290","created_at":"2021-01-18T14:23:12.967Z","updated_at":"2024-07-02T16:36:24.500Z","phase":"Phase 1","brief_title":"Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC","source_id_and_acronym":"NCT02929290","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" MET exon 14 mutation • MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BPI-9016"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/01/2017","start_date":" 03/01/2017","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2021-09-13"},{"id":"164de5d7-d0fe-446f-8ed5-922f4ae51531","acronym":"","url":"https://clinicaltrials.gov/study/NCT02544633","created_at":"2021-01-18T12:18:40.409Z","updated_at":"2024-07-02T16:36:49.218Z","phase":"Phase 2","brief_title":"Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET","source_id_and_acronym":"NCT02544633","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e glesatinib (MGCD265)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 04/30/2018","primary_completion_date":" 04/30/2018","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2020-03-04"},{"id":"0550fb9c-b9bd-4921-9d69-c2e4ef4dcbf9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00697632","created_at":"2021-01-18T02:36:31.892Z","updated_at":"2024-07-02T16:37:02.876Z","phase":"Phase 1","brief_title":"Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies","source_id_and_acronym":"NCT00697632","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" MET • AXL","pipe":" | ","alterations":" MET amplification • MET mutation • MET expression • AXL expression","tags":["MET • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET mutation • MET expression • AXL expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e glesatinib (MGCD265)"],"overall_status":"Completed","enrollment":" Enrollment 180","initiation":"Initiation: 06/01/2008","start_date":" 06/01/2008","primary_txt":" Primary completion: 09/01/2018","primary_completion_date":" 09/01/2018","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2019-02-12"}]